Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

egis pharmaceuticals plc, budapešť array - 15618 teriflunomid - potahovaná tableta - 14mg - teriflunomid

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 15618 teriflunomid - potahovaná tableta - 14mg - teriflunomid

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

orpha-devel handels und vertriebs gmbh, purkersdorf array - 9834 naltrexon-hydrochlorid - potahovaná tableta - 50mg - naltrexon

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

aop orphan pharmaceuticals gmbh, wien array - 9834 naltrexon-hydrochlorid - potahovaná tableta - 50mg - naltrexon

Unione Europea - ceco - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odmítnutí štěpu - imunosupresiva - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Unione Europea - ceco - EMA (European Medicines Agency)

ucb pharma sa - brivaracetam - epilepsie - antiepileptika, - briviact je indikován jako přídatná terapie při léčbě parciálních záchvatů s nebo bez sekundární generalizace u dospělých a dospívajících pacientů od 16 let věku s epilepsií.

Unione Europea - ceco - EMA (European Medicines Agency)

angelini pharma s.p.a - cenobamate - epilepsie - antiepileptika, - adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

bayer s.r.o., praha array - 4690 bifonazol - krém - 0,01g/g - bifonazol

Repubblica Ceca - ceco - SUKL (Státní ústav pro kontrolu léčiv)

bayer s.r.o., praha array - 4690 bifonazol - kožní roztok - 0,01g/g - bifonazol

Unione Europea - ceco - EMA (European Medicines Agency)

extrovis eu ltd. - lakosamid - epilepsie - antiepileptika, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.